ITA8314
ITA8314
ITA8314
from
$526.00
Price in reward points: 526
- Catalog: ITA8314
- Gene/Protein: BIRC7
- Product Description: Immunotag™ ML-IAP Antibody
-
Description
-
Specifications
Antibody Specification Datasheet 
IMPORTANT NOTE This product is custom manufactured with a lead time of 3-4 weeks. Once in production, this item cannot be cancelled from an order and is not eligible for return. Target Protein ML-IAP Clonality Polyclonal Storage/Stability -20°C/1 year Application WB,ELISA Recommended Dilution WB 1:1000-3000 Concentration 1 mg/ml Reactive Species Human Host Species Rabbit Immunogen A synthesized peptide derived from human ML-IAP Specificity ML-IAP Antibody detects endogenous levels of total ML-IAP Purification The antiserum was purified by peptide affinity chromatography. Form Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt Gene Name BIRC7 Accession No. Q96CA5 Alternate Names Baculoviral IAP repeat containing 7; Baculoviral IAP repeat containing protein 7; Baculoviral IAP repeat-containing protein 7; BIRC 7; birc7; BIRC7_HUMAN; KIAP; Kidney inhibitor of apoptosis protein; Livin; Livin inhibitor of apotosis; Melanoma inhibitor of apoptosis protein; ML IAP; ML-IAP; MLIAP; RING finger protein 50; RNF 50; RNF50; Description Apoptotic regulator capable of exerting proapoptotic and anti-apoptotic activities and plays crucial roles in apoptosis, cell proliferation, and cell cycle control. Its anti-apoptotic activity is mediated through the inhibition of CASP3, CASP7 and CASP9, as well as by its E3 ubiquitin-protein ligase activity. As it is a weak caspase inhibitor, its anti-apoptotic activity is thought to be due to its ability to ubiquitinate DIABLO/SMAC targeting it for degradation thereby promoting cell survival. May contribute to caspase inhibition, by blocking the ability of DIABLO/SMAC to disrupt XIAP/BIRC4-caspase interactions. Protects against apoptosis induced by TNF or by chemical agents such as adriamycin, etoposide or staurosporine. Suppression of apoptosis is mediated by activation of MAPK8/JNK1, and possibly also of MAPK9/JNK2. This activation depends on TAB1 and NR2C2/TAK1. In vitro, inhibits CASP3 and proteolytic activation of pro-CASP9. Isoform 1 blocks staurosporine-induced apoptosis. Isoform 2 blocks etoposide-induced apoptosis. Isoform 2 protects against natural killer (NK) cell killing whereas isoform 1 augments killing. Cell Pathway/ Category Primary Polyclonal Antibody Protein MW 32 kDa Usage For Research Use Only! Not for diagnostic or therapeutic procedures. - Reviews
| Antibody Specification | |
| Datasheet |
|
| IMPORTANT NOTE | This product is custom manufactured with a lead time of 3-4 weeks. Once in production, this item cannot be cancelled from an order and is not eligible for return. |
| Target Protein | ML-IAP |
| Clonality | Polyclonal |
| Storage/Stability | -20°C/1 year |
| Application | WB,ELISA |
| Recommended Dilution | WB 1:1000-3000 |
| Concentration | 1 mg/ml |
| Reactive Species | Human |
| Host Species | Rabbit |
| Immunogen | A synthesized peptide derived from human ML-IAP |
| Specificity | ML-IAP Antibody detects endogenous levels of total ML-IAP |
| Purification | The antiserum was purified by peptide affinity chromatography. |
| Form | Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt |
| Gene Name | BIRC7 |
| Accession No. | Q96CA5 |
| Alternate Names | Baculoviral IAP repeat containing 7; Baculoviral IAP repeat containing protein 7; Baculoviral IAP repeat-containing protein 7; BIRC 7; birc7; BIRC7_HUMAN; KIAP; Kidney inhibitor of apoptosis protein; Livin; Livin inhibitor of apotosis; Melanoma inhibitor of apoptosis protein; ML IAP; ML-IAP; MLIAP; RING finger protein 50; RNF 50; RNF50; |
| Description | Apoptotic regulator capable of exerting proapoptotic and anti-apoptotic activities and plays crucial roles in apoptosis, cell proliferation, and cell cycle control. Its anti-apoptotic activity is mediated through the inhibition of CASP3, CASP7 and CASP9, as well as by its E3 ubiquitin-protein ligase activity. As it is a weak caspase inhibitor, its anti-apoptotic activity is thought to be due to its ability to ubiquitinate DIABLO/SMAC targeting it for degradation thereby promoting cell survival. May contribute to caspase inhibition, by blocking the ability of DIABLO/SMAC to disrupt XIAP/BIRC4-caspase interactions. Protects against apoptosis induced by TNF or by chemical agents such as adriamycin, etoposide or staurosporine. Suppression of apoptosis is mediated by activation of MAPK8/JNK1, and possibly also of MAPK9/JNK2. This activation depends on TAB1 and NR2C2/TAK1. In vitro, inhibits CASP3 and proteolytic activation of pro-CASP9. Isoform 1 blocks staurosporine-induced apoptosis. Isoform 2 blocks etoposide-induced apoptosis. Isoform 2 protects against natural killer (NK) cell killing whereas isoform 1 augments killing. |
| Cell Pathway/ Category | Primary Polyclonal Antibody |
| Protein MW | 32 kDa |
| Usage | For Research Use Only! Not for diagnostic or therapeutic procedures. |